A Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and clinical activity of tadalafil, pembrolizumab, ipilimumab, and CRS-207 in subjects with metastatic pancreatic adenocarcinoma who have progressed after at least 1 prior chemotherapy regimen.
• Age ≥18 years.
• Have histologically or cytologically proven adenocarcinoma of the pancreas.
• Have previously treated metastatic disease.
• Have radiographic disease progression.
• Patients with the presence of at least one measurable tumor lesion.
• Patient's acceptance to have a tumor biopsy at baseline and on
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
• For both Women and Men, must use acceptable form of birth control while on study.
• Ability to understand and willingness to sign a written informed consent document.